An additional combination study of another anti-CD47 antibody, lemzoparlimab, had opened for patients with a higher-risk MDS or AML ineligible for intensive chemotherapy (NCT04912063) but was recently stopped. Here, CD47 is linked to myelodysplastic syndrome.